Cancer biosimilar drug Pelgraz is poised to hit the market after receiving a positive opinion by the Committee for Medicinal Products for Human Use (CHMP).
The Scottish Medicines Consortium (SMC) has recommended regular NHS funding for EUSA Pharma's kidney cancer drug Fotivda, enabling around 165 patients a year to access the treatment.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
